This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing MT
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115 MT
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group DJ
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent CI
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126 MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177 MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016 MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189 MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple... Our Logo
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Transcript : Regeneron Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Chart Regeneron Pharmaceuticals, Inc.
More charts
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
985 USD
Average target price
1,042 USD
Spread / Average Target
+5.78%
Consensus
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.
  5. Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,177 From $1,115, Keeps Overweight Rating